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Abstract. Humans homozygous or hemizygous for variants predicted to cause a loss of function 
(LoF) of the corresponding protein do not necessarily present with overt clinical phenotypes. We 
report here 190 autosomal genes with 207 predicted LoF variants, for which the frequency of 
homozygous individuals exceeds 1% in at least one human population from five major ancestry 
groups. No such genes were identified on the X and Y chromosomes. Manual curation revealed that 
28 variants (15%) had been misannotated as LoF. Of the 179 remaining variants in 166 genes, only 
11 alleles in 11 genes had previously been confirmed experimentally to be LoF. The set of 166 
dispensable genes was enriched in olfactory receptor genes (41 genes). The 41 dispensable 
olfactory receptor genes displayed a relaxation of selective constraints similar to that observed for 
other olfactory receptor genes. The 125 dispensable non-olfactory receptor genes also displayed a 
relaxation of selective constraints consistent with greater redundancy. Sixty two of these 125 genes 
were found to be dispensable in at least three human populations, suggesting possible evolution 
toward pseudogenes. Of the 179 LoF variants, 68 could be tested for two neutrality statistics, and 
eight displayed robust signals of positive selection. These variants included a known FUT2 variant 
that confers resistance to intestinal viruses, and an APOL3 variant involved in resistance to parasitic 
infections. Overall, the identification of 166 genes for which a sizeable proportion of humans are 
homozygous for predicted LoF alleles reveals both redundancies and advantages of such 
deficiencies for human survival. 
 
Significance statement. Human genes homozygous for apparent loss of function (LoF) variants are 
increasingly reported in a sizeable proportion of individuals without overt clinical phenotypes. Here, we 
found 166 genes with 179 predicted LoF variants for which the frequency of homozygous individuals 
exceeds 1% in at least one of the populations present in databases ExAC and gnomAD. These 
putatively dispensable genes showed relaxation of selective constraints suggesting that a considerable 
proportion of these genes may be undergoing pseudogenization. Eight of these LoF variants displayed 
robust signals of positive selection, including two variants in genes involved in resistance to infectious 
diseases. The identification of dispensable genes will facilitate the identification of functions that are 







The human genome displays considerable DNA sequence diversity at the population level. 
One of its most intriguing features is the homozygosity or hemizygosity for variants of protein-coding 
genes predicted to be loss-of-function (LoF) found at various frequencies in different human 
populations (1–3). An unknown proportion of these reported variants are not actually LoF, instead being 
hypomorphic or isomorphic, because of a re-initiation of translation, readthrough, or a redundant tail, 
resulting in lower, normal, or even higher than normal levels of protein function. Indeed, a bona fide 
nonsense allele, predicted to be LoF, can actually be gain-of-function (hypermorphic), as illustrated by 
IB mutations (4). Moreover, the LoF may apply selectively to one isoform or a subset of isoforms of 
a given gene, but not others (e.g. if the exon carrying the premature stop is spliced out for a specific 
set of alternative transcripts) (5). Finally, there are at least 400 discernible cell types in the human body 
(6), and the mutant transcript may be expressed in only a limited number of tissues. Conversely, there 
are also mutations not predicted to be LoF, such as in-frame insertions-deletions (indels), missense 
variants, splice-region variants affecting the last nucleotides (nt) of exons and even synonymous or 
deep intronic mutations, that may actually be LoF but cannot be systematically identified as such in 
silico.  
Many predicted LoF variants have nevertheless been confirmed experimentally, typically by 
demonstration of their association with a clinical phenotype. Of the 229,161 variants reported in HGMD 
(7), as many as 99,027 predicted LoF alleles in 5,186 genes have been found to be disease-causing 
in association and/or functional studies. For example, for the subset of 253 genes implicated in 
recessive forms of primary immunodeficiencies (8), 12,951 LoF variants are reported in HGMD. 
Conversely, a substantial proportion of genes harboring biallelic null variants have no discernible 
associated pathological phenotype, and several large-scale sequencing surveys in adults from the 
general population have reported human genes apparently tolerant to homozygous LoF variants (9–
14). Four studies in large bottlenecked or consanguineous populations detected between 781 and 
1,317 genes homozygous for mutations predicted to be LoF (10, 11, 13, 14). These studies focused 
principally on low-frequency variants (minor allele frequency, MAF<1%-5%), and associations with 
some traits, benign or disease-related, were found for a few rare homozygous LoF variants. Two 
studies provided a more comprehensive perspective of the allele frequency spectrum of LoF variants. 
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A first systematic survey of LoF variants, mostly in the heterozygous state, was performed with whole-
genome sequencing data from 185 individuals of the 1000 Genomes Project; it identified 253 genes 
with homozygous LoF variants (9). In a larger study of more than 60,000 whole exomes, the ExAC 
project identified 1,775 genes with at least one homozygous LoF variant, with a mean of 35 
homozygous potential LoF variants per individual (12).  
These studies clearly confirmed the presence of genes with homozygous LoF variants in 
apparently healthy humans, but no specific study of such variants present in the homozygous state in 
a sizeable proportion (>1%) of large populations has yet been performed. In principle, these variants 
may be neutral (indicating gene redundancy) (15), or may even confer a selective advantage (the so-
called “less is more” hypothesis) (3, 16). Indeed, a few cases of common beneficial LoF variants have 
been documented, including some involved in host defense against life-threatening microbes (17, 18). 
Homozygosity for LoF variants of DARC (now ACKR1), CCR5, and FUT2 confer resistance to 
Plasmodium vivax (19, 20), HIV (21–23), and norovirus (24, 25), respectively. We hypothesized that 
the study of common homozygous LoF variants might facilitate the identification of the set of 
dispensable protein-coding genes in humans and reveal underlying evolutionary trends. Unlike rare 
LoF variants, bona fide common homozygous LoF variants are predicted to be enriched in neutral 
alleles (1–3). They also provide indications concerning genes undergoing inactivation under positive 
selection (17, 18). The availability of large public databases, such as ExAC 
(http://exac.broadinstitute.org/, (12)) and its extended version gnomAD 
(http://gnomad.broadinstitute.org/), which includes data from more than 120,000 individuals, is making 
it possible to search for such variants with much greater power, across multiple populations. 
 
Results 
Definition of the set of dispensable protein-coding genes in humans 
We used two large exome sequence databases: the Exome Aggregation Consortium database 
(ExAC; (12)) and the Genome Aggregation Database (GnomAD; Methods), which have collected 
60,706 and 123,136 exome sequences, respectively. For this study, we focused on the 20,232 protein-
coding genes and we excluded the 13,921 pseudogenes (Methods; (26)). We defined protein-coding 
genes as dispensable if they carry variants that: (i) are computationally predicted to be loss-of-function 
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(LoF) with a high degree of confidence, including early stop-gains, indel frameshifts, and essential 
splice site-disrupting variants (i.e. involving a change in the 2-nt region at the 5’ or 3’ end of an intron; 
Methods); and (ii) have a frequency of homozygous individuals (hemizygous for genes on the X 
chromosome in males) exceeding 1% in at least one of the five population groups considered in these 
public databases (i.e. Africans, including African Americans, East Asians, South Asians, Europeans, 
and Admixed Latino Americans). As we focused on exome data, only small indels (<50 bp) were 
considered in this analysis. Common quality filters for calls and a minimum call rate of 80% were 
applied to each reference database (ExAC and GnomAD; Methods). Only LoF variants affecting the 
principal isoform (27) were retained (Methods). The application of these filters led to the detection of 
208 (ExAC) and 228 (GnomAD) genes, 190 of which were common to the two databases, and are 
referred to hereafter as the set of dispensable genes (Table 1 and Supplementary Table 1). No genes 
on the X or Y chromosomes fulfilled these criteria. Relaxing the thresholds on the SNP and INDEL call 
quality filters (variant quality score recalibration (VQSR) score; Methods), the variant call rate or the 
non-restriction to the principal isoform did not substantially increase the number of putatively 
dispensable genes (Supplementary Figures 1 and 2). The frequency of homozygous individuals at 
which a gene is defined as dispensable appeared to be the criterion with the largest impact on the 
number of dispensable genes identified, thereby justifying the use of the stringent threshold (>1% 
homozygotes in at least one specific population) described above (Supplementary Figures 1 and 2). 
 
Manual curation of the LoF variants 
We then investigated the potential molecular consequences of the 207 putative LoF variants 
retained, collectively associated with the 190 genes, by manually curating the annotation of these LoF 
variants. An examination of the sequencing reads in GnomAD showed that 18 variants — 10 single 
nucleotide variants (SNVs) and eight indels initially annotated as stop-gains and frameshift variants, 
respectively — were components of haplotypes with consequences other than the initial LoF annotation 
(Supplementary Table 1). Thus, for each of the 10 SNVs, a haplotype encompassing a contiguous 
second variant led to the creation of a missense rather than a stop variant allele. For each of the eight 
frameshift variations, a haplotype with a nearby second indel (observed in the same sequencing reads) 
collectively led to an in-frame indel allele. In addition, six essential splice site-disrupting variants caused 
by indels resulted in no actual modification of the splice receptor or acceptor site motif. Overall, 
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annotation issues occurred in about 13% of the initial set, indicating that there is a need for annotation 
methods to take the underlying haplotype inferred from sequencing reads into account. We also 
analyzed the common putative HLA-A LoF frameshift variant rs1136691 in more detail, as HLA-A null 
alleles are known to occur very rarely in large transplantation databases 
(http://hla.alleles.org/alleles/nulls.html). An analysis of the sequencing reads corresponding to this 
variant revealed an alternative haplotype of several variants, and a Blast analysis of this sequence 
yielded a perfect match with an alternative unmapped contig of chromosome 6 (chr6_GL000256v2_alt 
in GRCh38). This observation suggests that the alternative haplotype may have been wrongly mapped 
to the closest sequence in the reference genome, resulting in an artefactual frameshift in the HLA-A 
gene. This hypothesis is consistent with the known genomic complexity and high level of polymorphism 
of the HLA region, which can lead to incorrect mapping (28). Finally, we noted that one variant, 
rs36046723 in the ZNF852 gene, had an allele frequency >0.9999, suggesting that the reference 
genome carries the derived, low-frequency variant at this position. After curation, we retained 181 
predicted LoF variants from 168 genes (Table 1). 
 
Characteristics of the LoF variants 
The set of 181 predicted LoF variants defining the set of dispensable genes included premature 
stop-gains (40%), frameshifts (47%), and splice-site variants (13%; Figure 1). The variants could be 
classified further into those with a high or low predicted probability of being LoF (Methods): 27% 
presented features consistent with a low probability of LoF, whereas the remaining 73% were predicted 
to have more severely damaging consequences and were therefore considered to have a high 
probability of LoF (Figure 1 and Supplementary Figure 3). Despite possible differences in their 
impact, low- and high-probability LoF variants had similarly distributed global allele frequencies 
(Supplementary Figure 4; two-tailed Wilcoxon test p-value = 0.3115, based on ExAC allele 
frequencies; and 0.3341 based on GnomAD allele frequencies). Only 30 of the LoF variants finally 
retained were reported in at least one PubMed publication in the dbSNP database (29) 
(Supplementary Table 1). Manual inspection of these studies revealed that only 11 LoF variants had 
been experimentally demonstrated to abolish gene function (Supplementary Table 1). Focusing on 
the overlap between the 181 predicted LoF variants and the GWAS hits, we found that only two were 
reported in the GWAS catalog (30) as being significantly associated with a phenotypic trait: rs41272114 
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(LPA), associated with plasma plasminogen levels, lipoprotein A levels and coronary artery disease, 
and rs601338 (FUT2), associated with the levels of certain blood proteins, such as fibroblast growth 
factor 19. Finally, only 27 out of the 181 predicted LoF presented annotations in ClinVar, including 25 
of them labelled as benign / likely benign, one as protective/risk factor (rs5744168 in TLR5, discussed 
in later sections of this manuscript), and another as pathogenic (rs17147990 in HTN3) 
(Supplementary Table S1). Pathogenicity for rs17147990 is only based on a publication reporting this 
mutation in the Histatin 3 gene (p.Tyr47Ter) (31), without any evidence of causality for a clinical 
phenotype. Overall, this analysis shows that most of the common LoF considered here present features 
consistent with severely damaging variants for gene function, although experimental characterization 
is largely lacking. 
 
Overlap of dispensable genes with disease-causing and essential genes 
We then explored the features characterizing the list of 168 putatively dispensable genes, and 
searched for those previously shown to be (i) associated with Mendelian diseases (n=3,622, OMIM 
(32)), or (ii) essential in human cell lines (n=1,920) or knockout mice (n=3,246) (33) (Methods). We 
focused on LoF variants predicted to be severely damaging, as described above (Figure 1). We found 
that three LoF variants from our list affected OMIM genes (CLDN16, TMEM216, GUF1; Table 2), 
whereas none affected essential genes (Fisher’s exact p-value = 7.727e-06 and 6.249e-10 for human 
cell lines and knockout mice essential genes, respectively). It has been suggested that the common 
LoF variant rs760754693 of CLDN16 — a gene associated with a renal disorder known as familial 
hypomagnesemia with hypercalciuria and nephrocalcinosis — affects the 5’-untranslated region of the 
gene rather than its coding sequence (34). A second methionine residue downstream from the affected 
position in CLDN16 could potentially serve as the actual translation start site. The TMEM216 variant 
rs10897158 is annotated as benign in ClinVar (35). TMEM216 is required for the assembly and function 
of cilia, and pathogenic mutations of this gene cause Joubert, Meckel and related syndromes (36). The 
canonical transcript of TMEM216 encodes a 145-amino acid protein. The rs10897158 splice variant 
(global frequency of homozygous individuals >70%) results in the synthesis of a longer protein (148 
amino acids) corresponding to the most prevalent isoform (36), which could probably be considered to 
be the reference protein in humans. There is currently little evidence to support the third variant, 
rs141526764 (GUF1), having any pathogenic consequences. The association of GUF1 with Mendelian 
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disease (early infantile epileptic encephalopathy) is reported in OMIM as provisional and based solely 
on the finding of a homozygous missense variant (A609S) in three siblings born to consanguineous 
parents (37). For all subsequent analyses, we filtered out the two variants considered highly likely not 
to be LoF (rs760754693, rs10897158), resulting in a final list of 179 predicted LoF variants 
corresponding to 166 genes (Table 1). The absence of common LoF variants predicted with a high 
degree of confidence in disease genes or essential genes is consistent with these genes being 
dispensable. 
 
Features of the set of putative dispensable protein-coding genes 
We characterized the set of 166 putatively dispensable protein-coding genes further by 
performing a Gene Ontology (GO) enrichment analysis (Methods). We found a significant 
overrepresentation of genes involved in G-protein coupled receptor activity and related GO terms 
(Fisher’s exact p-value= 5.50e-25; Supplementary Table 2). Such enrichment was driven by the 
presence of 41 olfactory receptor (OR) genes, accounting for 25% of the total set of dispensable genes, 
consistent with previous analyses (9). We then stratified dispensable genes according to their 
mutational damage, assessed by calculating the GDI score (38). The GO enrichment analyses 
conducted separately for the two sets gave very similar results, driven by the OR genes in both cases 
(Supplementary Table 2). After the removal of ORs, no additional functional categories were identified 
as displaying significant enrichment (Supplementary Table 2). Thus, a large number of protein-coding 
genes may be dispensable, but this has no apparent impact at the level of pathways or functional 
categories. Based on previous findings and the known specific features of OR genes (39, 40), we opted 
to consider the 41 OR and 125 non-OR dispensable genes separately in subsequent analyses (Table 
1). In comparisons with a reference set of 382 OR, and 19,850 non-OR protein-coding genes 
(Methods), the coding lengths of the 41 OR (median = 945 nt) and the 125 non-OR (median = 1153.5 
nt) dispensable genes were not significantly different from those of the corresponding non-dispensable 
OR (median = 945 nt; Wilcoxon test p-value= 0.6848) and non-OR (median = 1275 nt; Wilcoxon test 
p-value=0.1263) genes. The genomic distribution of dispensable OR genes displayed some clustering 
on some chromosomes, but did not differ significantly from that of the reference OR genes 
(Supplementary Figure 5A). The distribution of dispensable non-OR genes across autosomal 
chromosomes was also similar to that for the reference set, except that no dispensable genes were 
9 
 
present on the X and Y chromosomes (Supplementary Figure 5B). This finding suggests that 
common LoF variants on sexual chromosomes have been more efficiently purged from the population 
than autosomal variants, presumably because they have pathogenic effects in hemizygous males. 
 
 
Organ expression patterns of the dispensable protein-coding genes 
We then investigated the expression patterns of the 166 putatively dispensable genes across 
organs and leukocyte types. For organs, we used RNA-seq expression data from the Illumina Body 
Map project (IBM) and the GTEX project, and for leukocytes, we used data from the BluePrint project 
(Methods; Supplementary Table 3). Most of the dispensable OR (30 of 34, 88%) were not found to 
be expressed in any of the datasets considered, consistent with the general expression pattern for all 
OR genes (328 of 355 OR genes not expressed, 92%; Figure 2). We found that 996 of a reference set 
of 17,948 non-OR protein-coding genes were not expressed in any of the databases considered 
(referred to hereafter as non-detected genes). Interestingly, the non-detected genes displayed a 
significant enrichment in dispensable genes relative to the reference set: odds ratio (OR): 3.34, 95% 
confidence interval (CI) 1.92-5.53, Fisher’s exact test p-value 2.29e-05 (Figure 2). A similar pattern 
was observed for organ-specific genes, which were defined as genes expressed in <20% of the organs 
evaluated in the corresponding dataset: OR of 2.09 (CI 1.38-3.11) for IBM, p-value=3.67e-04, and OR 
of 3.56 (CI 2.41-5.22) for GTEX, p-value=1.53e-10. We further characterized the distribution of non-
OR dispensable genes among the organ-specific genes for the various organs evaluated. Consistent 
with previous observations (11), the brain appeared to be the only organ in which the proportion of 
dispensable genes was significantly lower than that observed for organ-specific genes in both the IBM 
and the GTEX datasets: OR of 0.23 (CI 0.04-0.72), p-value=5.47e-03, and OR of 0.08 (CI 0.002-0.45), 
p-value=2.69e-04, respectively (Supplementary Table 4). Organ-pervasive genes were also found to 
be significantly depleted of dispensable genes, reflecting a lower degree of redundancy: OR of 0.09 
(CI 0.04-0.18), p-value=6.47e-20 for IBM, and OR of 0.16 (CI 0.09-0.26), p-value=8.04e-19 for GTEX. 
The number of organs in which a gene is expressed was consistently, and negatively associated with 
the proportion of dispensable genes (linear regression p-values after adjustment for coding sequence 
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length < 2e-16 for both IBM and GTEX). Overall, genes widely expressed or specifically expressed in 
the brain are less dispensable than those with a more restricted pattern of expression. 
 
Expression patterns for dispensable genes in leukocytes  
We then investigated the expression patterns of the 166 putatively dispensable genes in 
leukocytes. Human immune genes were classified on the basis of the RNA-seq data generated by the 
BluePrint project (41). We identified 7,323 adaptive leukocyte-expressed genes on the basis of their 
expression in B or T cells in at least 20% of the samples considered, and 9,039 innate leukocyte-
expressed genes defined on the basis of their expression in macrophages, monocytes, neutrophils, or 
dendritic cells (DC) in at least 20% of the samples considered (Supplementary Table 3). We are 
aware that the main function of DCs is to present antigens to T cells, making their classification as 
“innate” both arbitrary and questionable. These leukocyte-expressed genes included no OR genes, 
and all the results therefore correspond to non-OR genes. A significant depletion of dispensable non-
OR genes relative to the reference set was observed among the genes expressed in adaptive and 
innate leukocytes: OR of 0.20 (95% CI 0.10-0.34), p-value=8.80e-12, and OR of 0.20 (CI 0.12-0.33), 
p-value=9.98e-14, respectively; Figure 2). In total, 24 dispensable genes were identified as expressed 
in adaptive leukocytes (n=4 genes), innate leukocytes (n=10) or both (n=10). Detailed information 
about the common homozygous LoF variants of these genes is presented in Supplementary Table 5. 
Sixteen of these 24 genes had variants predicted to have highly damaging consequences, including a 
well-known stop-gain variant of TLR5 (42). This truncating TLR5 variant, which abolishes cellular 
responses to flagellin, appears to have evolved under neutrality (43). These genes also included 
APOL3, which is known to be involved in the response to infection with African trypanosomes (44). 
Thus, genes widely expressed in leukocytes are generally less dispensable than the reference set. 
However, specific immune-related genes may become LoF-tolerant due to functional redundancy (e.g. 
TLR5) or positive selection, by increasing protective immunity, for example. This aspect is considered 
in a subsequent section. 
 
Population distribution of the dispensable genes 
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We analyzed the distribution of the dispensable genes across the five specific populations 
considered: Africans (including African-Americans), East Asians, South Asians, Europeans (including 
Finnish), and Americans of Latino descent (Figure 3). Of the 125 non-OR genes, we found that 33 
were dispensable in all populations, 16 in four populations, and 13 in three populations (homozygous 
LoF frequency >1% in each population). Conversely, 48 genes were population-specific, with Africans 
providing the largest fraction in both absolute (26 genes) and relative terms, as a reflection of their 
greater genetic diversity (45). The remaining 15 genes were found in two populations. Almost half the 
41 dispensable OR were common to all five populations (n=19), 10 were present in four or three 
populations, two were present in two populations, and 10 were population-specific (including nine in 
Africans). As expected, the number of populations in which a gene was found to be dispensable 
correlated with the maximum frequency of homozygous individuals in the populations concerned 
(Supplementary Figure 6). Overall, 49% of the non-OR and 71% of the OR dispensable genes (>90% 
of the dispensable OR genes in non-African populations) were common to at least three human 
populations, suggesting a general process of tolerance to gene loss independent of the genomic 
background of the population. 
 
Negative selection of dispensable genes 
We then investigated the behavior of dispensable genes in terms of the functional scores 
associated with gene essentiality and selective constraints (Figure 4). We first evaluated a metric that 
was designed to assess the mutational damage amassed by a gene in the general population (GDI 
(38)) and three gene-level scores that measure the extent of recent and ongoing negative selection in 
humans (RVIS (46), pLI and pRec (12); Methods). Consistent with expectations, dispensable non-OR 
genes had much higher GDI (two-tailed Wilcoxon test p-value=6.52e-35), higher RVIS (p-value=1.30e-
37), and lower pLI (p-value=1.548597e-22) values than non-dispensable non-OR genes (Figure 4), 
whereas no significant differences were found for pRec values (p-value=0.29). In analyses focusing on 
OR genes, GDI and RVIS values were also significantly higher for dispensable genes than for non-
dispensable genes (p-values= 3.08e-06 and 1.96e-02, respectively), whereas no differences were 
found for the pLI and pRec distributions (p-value>0.05). When restricting the assessment of the GDI 
score to missense variants, the same trends where observed: p-value=1.24e-15 and 1.44e-02, for non-
OR and OR comparisons, respectively. We then evaluated the strength of negative selection at a 
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deeper evolutionary level, using two inter-species conservation scores: the estimated proportion f of 
non-lethal non-synonymous mutations (47), which was obtained with SnIPRE, by comparing 
polymorphism within humans and divergence between humans and chimpanzee at synonymous and 
non-synonymous sites (48), and the GerpRS conservation score, obtained from alignments of 
sequences from multiple mammalian species (excluding humans) (49). Neither the f nor the GerpRS 
values obtained differed significantly (p-value >0.01) between dispensable and non-dispensable OR 
genes (Figure 4). However, dispensable non-OR genes had higher f and GerpRS values than non-
dispensable non-OR genes (p-value= 1.51e-29 and = 9.70e-28, respectively), indicating that 
dispensable non-OR genes were more tolerant to non-synonymous variants than non-dispensable 
non-OR genes. Dispensable genes also had more human paralogs than other protein-coding genes 
(p-value= 8.76e-06), suggesting a higher degree of redundancy. For OR genes, the number of paralogs 
did not differ between dispensable and non-dispensable genes, further confirming that the negative 
selection parameters of dispensable and non-dispensable genes OR genes were similar. Overall, 
these results reveal a relaxation of the selective constraints acting at dispensable non-OR gene loci 
relative to non-dispensable genes, providing further evidence for evolutionary dispensability. 
 
Positive selection of common LoF variants 
We investigated the possibility that the higher frequency of some LoF mutations was due to a 
selective advantage conferred by gene loss (i.e., the “less-is-more” hypothesis), by searching for 
population-specific signatures of positive selection acting on these variants (17, 18). We considered 
two neutrality statistics: FST, which measures between-population differences in allele frequencies at a 
given locus (50), and integrated haplotype score (iHS) (51), which compares the extent of haplotype 
homozygosity around the ancestral and derived alleles in a given population. Both statistics could be 
computed for 68 variants fulfilling the quality control criteria (Methods). Considering a cutoff point of 
the 95th genome-wide percentile for each statistic (Figure 5), we detected 39 common LoF alleles in 
putatively dispensable genes displaying signals suggestive of positive selection, as attested by their 
low iHS (n=7), high FST values (n=24), or both (n=8; Supplementary Table 6). Seven of these variants 
in OR genes had only high FST values, suggestive of genetic drift related to the ongoing 
pseudogenization of ORs (40). We also noted that the LoF mutation (rs2039381) of IFNE displayed 
significant levels of population differentiation (e.g. FST=0.25 for GIH vs. CEU, Pemp = 0.002). This result 
13 
 
is intriguing as IFNE encodes IFNε, which plays an important role in protective immunity against 
microbes in the female reproductive tract in mice (52, 53). This nonsense variant (Q71X) is predicted 
to decrease the length of the encoded protein by two thirds, but this has not been validated 
experimentally. The proportion of homozygotes is highest in East Asia (3.5%) and South Asia (2%), is 
much lower in Europe (0.02%), and does not differ between males and females. The iHS scores were 
not significant for this variant (Supplementary Figure 7), and neither were other selection scores, such 
as Tajima’s D, Fu and Li’s D* and F *, and Fay and Wu’s H, previously obtained in a large evolutionary 
genetic study of human interferons (54). In light of these observations, the most likely explanation for 
the high FST observed at this locus is genetic drift.  
 
LoF mutations of FUT2 and APOL3 are under positive selection  
Eight common LoF variants provided more robust evidence for positive selection, as they had 
both a high FST and a low iHS (Supplementary Table 6, Figure 5). For five of these variants, there 
was no obvious relationship between the gene concerned and a possible selective advantage. 
However, one variant with a high FST (FST = 0.25 for ITU vs. CHB, Pemp= 0.012) and a low iHS ( iHS -
2.33, Pemp = 0.004 in CHS) was located in SLC22A14, which has been shown to be involved in sperm 
motility and male infertility in mice (55). Finally, the two remaining variants were in the FUT2 and APOL3 
genes, which are known to be involved in defense against infections. Consistent with previous 
observations, we observed high FST values (FST = 0.54 for CEU vs. CHS, Pemp= 0.002) and extended 
haplotype homozygosity iHS =-1.7, Pemp = 0.03 in CEU) around the LoF mutation (rs601338) in FUT2 
(Supplementary Figure 7). This gene is involved in antigen production in the intestinal mucosa, and 
null variants are known to lead to the non-secretor phenotype conferring protection against common 
enteric viruses, such as norovirus (25, 56), and rotavirus (57, 58). We also identified a novel hit at the 
APOL3 LoF variant rs11089781. This nonsense variant (Q58X) was detected only in African 
populations (15-33% frequency), in which it had a low iHS (iHS=-2.75 in MSL, Pemp = 0.001), indicating 
extended haplotype homozygosity around the LoF mutation in these populations (Supplementary 
Figure 7). APOL3 is located within a cluster of APOL genes including APOL1. These two members of 
the six-member APOL cluster, APOL1 and APOL3, are known to be involved in defense against African 
trypanosomes (59, 44). These analyses indicate that, although positive selection remains rare in 
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We identified 166 putatively dispensable human protein-coding genes. Even after manual 
curation, it is likely that a certain proportion of the variants retained for these genes are not actually 
LoF, and the availability of experimental validation for only a small fraction of the predicted LoF variants 
is one of the limitations of this study. It is also likely that additional dispensable genes could be detected 
in the general population on the basis of common homozygosity for other types of genetic variants 
abrogating protein function, notably those for which whole-exome sequencing is not particularly 
suitable, such as deletions of more than 50 nucleotides (60). The putatively dispensable human protein-
coding genes identified included 120 that overlapped either with the total list of 2,641 genes apparently 
tolerant to homozygous rare LoF reported from bottlenecked or consanguineous populations (10, 11, 
13, 14) or with the list of 253 genes initially identified from individuals of the 1000 Genomes Project (9) 
(Supplementary Figure 8), or both. These partly discordant results are probably due to differences in 
study designs, in particular in terms of sample sizes, population structures, and frequencies of the LoF 
variants studied. Most of the 46 genes specific to our study had a maximum homozygote frequency 
below 0.05 or had a higher frequency in only one or two of the five studied populations, as for FUT2 
and IFNE. Our set of dispensable genes was strongly enriched in OR genes, as previously reported 
(9, 61). However, dispensable OR genes had no particular features distinguishing them from non-
dispensable OR genes other than slightly higher GDI and RVIS values. This finding is consistent with 
the notion that the number of functional ORs has decreased during evolution in humans (62), and 
provides evidence for ongoing pseudogenization (63, 40). Conversely, dispensable non-OR genes 
displayed a strong relaxation of selective constraints relative to non-OR non-dispensable genes at both 
the inter-species and intra-species levels. In addition, the set of dispensable non-OR genes was 
depleted of genes widely expressed in the panel of organs evaluated, brain-specific genes and genes 
expressed in leukocytes. This suggests that the redundancy observed for some microbial sensors and 
effectors (64, 18) does not necessarily translate into higher rates of gene dispensability. 
The set of dispensable genes identified here probably largely corresponds to genes 
undergoing pseudogenization (65, 66) due to present-day superfluous molecular function at the cell, 
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organ or organism levels, or a redundant function in the genome that may be recovered (e.g. by 
paralogous genes or alternative pathways). This is consistent with the observation that most of the 
dispensable genes were common to at least three human populations. The overlap was particularly 
large for OR genes, which are strongly enriched in dispensable genes, and generally present a strong 
relaxation of selective constraints and signs of ongoing pseudogenization (40). Another example is 
provided by TLR5, encoding a cell-surface receptor for bacterial flagellin, which harbors a dominant 
negative stop mutation at high population frequencies (43, 42, 67). This finding is consistent with the 
notion that a substantial proportion of modern-day humans can survive with complete TLR5 deficiency 
(42). These observations also suggest that additional mechanisms of flagellin recognition, such as 
those involving the NAIP-NLRC4 inflammasome (68, 69), may provide sufficient protection in the 
absence of TLR5. Finally, 45 of our dispensable genes belong to the set of 2,278 Ensembl/GENCODE 
coding genes recently reported to display features atypical of protein-coding genes (70). Our study 
may therefore provide additional candidates for inclusion in the list of potential non protein-coding 
genes. 
High population frequencies of LoF variants may also reflect recent and ongoing processes of 
positive selection favoring gene loss (i.e. the “less-is-more” paradigm) (17). Two of the eight variants 
with the most robust signals of positive selection were located in genes involved in resistance to 
infectious diseases. The FUT2 gene is a well-known example of a gene for which loss is an advantage, 
as it confers Mendelian resistance to common enteric viruses and has a profile consistent with positive 
selection. However, non-secretor status has also been associated with predisposition to Crohn’s 
disease (71), Behçet’s disease (72), and various bacterial infections (73), including otitis media (74), 
suggesting an advantage for secretor status. Accordingly, an evolutionary genetics study concluded 
that FUT2 genetic diversity was compatible with the action of both positive and balancing selection on 
secretor status (75). An interesting new finding from this study is provided by the APOL3 LoF variant 
(rs11089781), which we found to display signals of recent, positive selection in Africans. APOL3 and 
APOL1 are known to be involved in the response to African trypanosomes (44). Two variants encoding 
APOL1 proteins with enhanced trypanolytic activity are present only in African populations, in which 
they harbor signatures of positive selection despite increasing the risk of kidney disease (76). 
Interestingly, the APOL3 LoF variant was also recently associated with nephropathy independently of 
the effect of the two late-onset kidney disease-risk APOL1 variants, which are not in strong linkage 
16 
 
disequilibrium with rs11089781 (77). A physical interaction occurs between APOL1 and APOL3 (77), 
and APOL1 may protect against pathogens more effectively when not bound to APOL3. Similar 
mechanisms may, therefore, be involved in the positive selection of the APOL1 kidney disease-risk 
alleles and the APOL3 LoF variant in African populations. Additional common LoF homozygotes could 
probably be further identified in other unstudied populations, or involving variants not currently 
predicted to be LoF in silico. Improvements in the high-confidence identification of dispensable genes 
will make it possible to identify biological functions and mechanisms that are, at least nowadays, 
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Exome sequencing data 
Human genetic variants from the Exome Aggregation Consortium (ExAC) database (12) 
(http://exac.broadinstitute.org/) were downloaded on September 9th 2016, release 0.3.1, non-TCGA 
subset. Variants from Exome data of the Genome Aggregation Database (gnomAD, 
http://gnomad.broadinstitute.org/) were obtained on February 28th 2017, release 2.0.1. For consistency 
with ExAC and GnomAD pipelines, variants were annotated with the Ensembl Variant Effect Predictor 
VEP (78) (v81 for ExAC, v85 for gnomAD), with loss-of-function (LoF) annotations from LOFTEE ((12) 
https://github.com/konradjk/loftee). Homo sapiens genome build GRCh37/hg19 was used with both 
databases. Analyses were restricted throughout this study to a background set of 20232 human 
protein-coding genes obtained from BioMart Ensembl 75, version Feb 2014 (GRCh37.p13; (79)). 
Protein-coding genes were defined as those containing an open reading frame (ORF). By contrast, 
pseudogenes were typically defined as gene losses resulting from fixations of null alleles that occurred 
in the human lineage after a speciation event, some of them may actually be human-specific, i.e. fixed 
after the human-chimpanzee divergence. However, the definition might be larger, including the so-
called processed pseudogenes, corresponding to DNA sequences reverse-transcribed from RNA and 
randomly inserted into the genome (65, 66). A total of 20,232 protein-coding genes and 13,921 
pseudogenes were reported by Ensembl following the Ensembl Genebuild workflow incorporating the 
HAVANA group manual annotations (26). Among the protein-coding genes, 382 genes were identified 
with a gene name starting with “Olfactory receptor” (Supplementary Table 7). 
VEP annotations were done against the set of Ensembl Transcript IDs associated to Ensembl protein 
coding genes, focusing on the canonical transcript as described in the ExAC Flagship paper (Lek et 
al.). This was done through VEP option “--canonical”, which provides the variant consequence for what 
is considered to be the “canonical transcript” of a gene. As reported in (80) and further detailed in 
Ensembl documentation (http://www.ensembl.org/info/website/glossary.html) for human, the canonical 
transcript for a gene is set according to the following hierarchy: (1) Longest CCDS translation with no 
stop codons. (2) If no (1), choose the longest Ensembl/Havana merged translation with no stop codons. 
(3). If no (2), choose the longest translation with no stop codons. (4). If no translation, choose the 
longest non-protein-coding transcript. However, as acknowledged in the Ensembl documentation, the 
canonical transcript does not necessarily reflect the most biologically relevant transcript of a gene. For 
the purpose of this study, we thus further focused on variants affecting canonical transcripts when 
these are considered in turn the “principal isoform” of the associated gene, i.e. its most functionally 
important transcript. To that aim, we used transcript annotations from the APPRIS database (28) 
(downloaded on downloaded March 2nd 2017, using Gencode19/Ensembl74). APPRIS is a system to 
annotate principal isoforms based on a range of computational methods evaluating structural 





Loss-of-function variants and definition of the set of dispensable genes 
Loss-of-function (LoF) variants were considered here as those predicted to lead to an early stop-gain, 
indel frameshift or essential splice-site disruption (i.e, splice-site donor and splice-site acceptor 
variants). Following the criteria used in the ExAC flagship paper (12), only variants with a genotype 
quality ≥ 20, depth ≥ 10, a call rate > 80%, mapped to canonical isoforms and labeled as “high-
confidence” LoF variants by LOFTEE, were retained. LOFTEE ((12), https://github.com/konradjk/loftee) 
is a VEP plugin allowing to flag and filter variants according to quality control criteria characteristic of 
falsely considered LoF variants. Thus, the following low-confidence LoF variants flagged by LOFTEE 
were filtered out: variants for which the purported LoF allele is the ancestral state (across primates), 
stop-gain and frameshift variants in the last 5% of the transcript, or in an exon with non-canonical splice 
sites around it (i.e. intron does not start with GT and end with AG), and splice-site variants in small 
introns (<15 bp), in an intron with a non-canonical splice site or rescued by nearby in-frame splice sites. 
In a previous work we showed that features associated to low-confidence loss-of-function variants are 
enriched in  common (AF>5%) and in homozygous LoF in the general population (5). Consistent with 
such observation, putatively false LoF variants filtered by LOFTEE are enriched in common variants 
(81), and would confound the detection of dispensable genes as defined above unless they are filtered 
out. Following https://macarthurlab.org/2016/03/17/reproduce-all-the-figures-a-users-guide-to-exac-
part-2/, variants in the top 10 most-multiallelic kilobases of the human genome were filtered out, i.e: 
Chr14:106330000-106331000; Chr2:89160000-89161000; Chr14:106329000-106330000; 
Chr14:107178000-107179000; Chr17:18967000-18968000; Chr22:23223000-23224000; 
Chr1:152975000-152976000; Chr2:89161000-89162000; Chr14:107179000-107180000; 
Chr17:19091000-19092000. For GnomAD variants, a heterozygote genotype allele balance > 0.2 was 
further required. In addition to the previous criteria, a set of filters for LoF variants was adopted in this 
work, retaining variants with a variant quality score recalibration (VQSR) equal to ‘PASS’ both for single 
nucleotide polymorphisms (SNPs) and frameshifts and affecting the APPRIS principal isoform (27) as 
described above. Dispensable genes were defined as those presenting a LoF variant with a frequency 
of homozygous individuals higher than 1% in at least one of the 5 main populations considered, i.e.: 
Africans (including African Americans), East Asians, South Asians, Europeans (Finnish and Non-
Finnish), and Americans.  
Impact prediction of LoF variants 
The mRNA region capable of triggering transcript degradation by NMD upon an early stop-gain was 
defined as in a previous study (5), according to HAVANA annotation guidelines (v.20). Specifically, the 
NMD-target region of a transcript was defined as those positions more than 50 nucleotides upstream 
from the 3’-most exon-exon junction. Transcripts bearing stop-gain variants in these regions are 
predicted to be degraded by NMD (82). Molecular impact prediction of splice-disrupting variants was 
performed with Human Splicing Finder (HSF) software ((83); online version 3.1 available at 
http://www.umd.be/HSF/ with default parameters). HSF classifies splicing variants into five categories: 
unknown impact, no impact, probably no impact, potential alternation, most probably affecting variant. 
LoF variants were classified into those predicted to be LoF with low and high probability. Low-
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probability LoF arbitrarily include (i) stop-gains and frameshift variants truncating the last 15% of the 
protein sequence, which might translate into small truncations in the final protein, or mapping into the 
first 100 nucleotides of the transcript, which has been reported as a window length in which LoF variants 
are often recovered by means of alternative start site usage (84); and (ii) essential splice site variants 
with an unknown or low computationally predicted impact on splicing motifs based on position weight 
matrices, maximum entropy and motif comparison methods (Methods). High-probability LoF variants 
include (i) stop-gains and frameshifts truncating more than 15% of the protein sequence or occurring 
in a region prone to transcript degradation by NMD, which probably result in the complete abolition of 
protein production (Methods); and (ii) putative splice-site variants with an intermediate or high 
computationally predicted impact (Methods). All associations of LoF variants reported in the GWAS 
catalog (version v1.0, date 2019-01-11) were downloaded from ftp://ftp.ebi.ac.uk/pub/databases/gwas/. 
As for Clinvar annotations, the 2020/03/02 release was used (35). 
Gene Ontology enrichment analysis 
Gene Ontology enrichment analysis was performed with DAVID functional annotation tool (85). Only 
terms with a Benjamini-corrected Fisher’s exact test p-value < 0.05 were retained. 
Gene expression patterns across human organs and immune cell types 
Two lists of organ and tissue-expressed genes were defined on the basis of the RNA-seq expression 
data from the Illumina Body Map project (IBM, 15,688 expressed genes), and the GTEX project (16,762 
expressed genes). First, RNA-seq expression data from a panel of 11 human organs and tissues (one 
sample each) from the Illumina Body Map project (IBM) were extracted from the Expression Atlas 
database (EBI accession E-MTAB-513; 1 February 2017 release; 
https://www.ebi.ac.uk/gxa/experiments/E-MTAB-513/Results). The list of organs and tissues included: 
adipose tissue, brain, breast, colon, heart, kidney, liver, lung, ovary, skeletal muscle tissue, and testis. 
It should be noted that leukocyte, lymph node, adrenal, prostate and thyroid gland data were removed 
from these datasets. A total of 15,688 organ-expressed genes were defined as being expressed in 
more than 3 transcripts per million (TPM; according to (86)) in at least one of the IBM samples 
considered. Second, RNA-seq expression data from a panel of 24 human organs (multiple samples 
per organ) from the GTEX project (87) were extracted from 
https://gtexportal.org/home/tissueSummaryPage (version V6p). Blood, blood vessel, salivary gland, 
adrenal gland, thyroid, pituitary and bone marrow data were removed from these datasets. A total of 
16,762 organ-expressed genes were defined as being expressed in more than 3 TPM in at least 20% 
of the samples from at least one GTEX organ. The organ-expressed set of genes previously defined 
was further classified into a set of “organ-specific genes” and “organ-pervasive genes”, depending on 
whether the gene was defined as expressed in <20% (organ-specific) or >80% of the organs and tissue 
types evaluated in the corresponding dataset (i.e. IBM or GTEX). 
In addition, the RNA-seq dataset generated by the BluePrint project (41) was used as a reference set 
for gene expression for the different immune cell types from human venous blood (August 19, 2017 
release, data available at http://dcc.blueprint-epigenome.eu/#/files). Only cell types with more than two 
samples were considered. In total, 85 libraries were retained, including: 9 B-cell and 17 T-cell samples 
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(collectively considered as adaptive immune cell types), and 15 monocyte, 25 macrophage, 6 dendritic 
cell and 13 neutrophil samples (collectively considered as innate immune cell types). A total of 7,346 
adaptive immune cell-expressed genes were detected as those expressed in more than 3 TPM in B 
cells or T cells in at least in 20% of the corresponding samples collectively considered. Similarly, 9,069 
innate immune cell-expressed genes were defined here as expressed in more than 3 TPM in 
macrophages, monocytes, neutrophils, or dendritic cells in at least 20% of the corresponding samples 
collectively considered. Full details about the libraries used, as provided by the BluePrint project, are 
reported in Supplementary Table 8. The set of genes not found to be expressed in any of the previous 
lists was determined from the complement of the reference list of 20120 protein-coding genes defined 
as Ensembl Biomart, release 75 (79). 
 
Gene-level annotations 
The following gene-level features associated with natural selection were obtained: gene damage index 
(GDI) scores, a gene-level metric of the mutational damage that has accumulated in the general 
population, based on CADD scores, were taken from (38). High GDI values reflect highly damaged 
genes. The residual variation intolerance score (RVIS percentile, provided in (46)), assesses the gene’s 
departure from the mean number of common functional mutations in genes with a similar mutational 
burden in humans. High RVIS percentiles reflect genes that are highly tolerant to variation. The gene 
probability of loss-of-function intolerance (pLI, (12)), estimating the depletion of rare and de novo 
protein-truncating variants relative to expectations derived from a neutral model of de novo variation 
on ExAC exomes data, and pRec, estimating gene intolerance to two rare and de novo protein-
truncating variants (analogous to recessive genes) were obtained from the ExAC Browser (release 
0.3.1, (12)). pLI and pRec values close to 1 indicate gene intolerance to heterozygous and homozygous 
loss-of-function and to homozygous mutations, respectively. “f” values were obtained through SnIPRE 
(48) as described in (47), based on a comparison of polymorphism and divergence at synonymous and 
non-synonymous sites. GerpRS scores (49) were downloaded from 
http://mendel.stanford.edu/SidowLab/downloads/gerp/. Data on the number of human paralogs for 
each gene were collected from the OGEE database (88). Monogenic Mendelian disease genes were 
obtained as described in Chong et al. (89): OMIM raw data files were downloaded from (90). Phenotype 
descriptions containing the word ‘somatic’ were flagged as ‘somatic’, and those containing ‘risk', 
'quantitative trait locus', 'QTL', '{', '[' or 'susceptibility to’ were flagged as ‘complex’. Monogenic 
Mendelian genes were defined as those having a supporting evidence level of 3 (i.e. the molecular 
basis of the disease is known) and not having a ‘somatic’ or ‘complex’ flag. (Supplementary Table 7). 
Genes essential in human cell lines and in knockout mice were obtained from (33) (Supplementary 
Table 7).  
 
Genome-wide scans for recent positive selection at loss-of-function mutations 
We tested for the occurrence of positive selection of loss-of-function mutations, by calculating two 
neutrality statistics: the interpopulation FST, which identifies loci displaying high levels of variation in 
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allele frequencies between groups of populations (50), and the intrapopulation integrated haplotype 
score (iHS) (51), which compares the extent of haplotype homozygosity at the ancestral and derived 
alleles. Positive selection analyses were confined to biallelic SNPs found in the 1000 Genomes Project 
phase 3 data (91), including 2,504 individuals from 26 populations, assigned to five meta-populations 
and predicted to have severely damaging consequences.  (Supplementary Table 9). Multiallelic 
SNPs, SNPs not detected in the 1000 Genomes Project and indel frameshifts were discarded in the 
positive selection analysis. For FST calculation, we investigated a total of 75 LoF mutations that passed 
quality filters, and compared the allele frequencies of these variants in 26 populations, to the allele 
frequencies of the same mutations in the European (CEU) and African (YRI) reference populations 
(Supplementary Table 9). More specifically, we compared allele frequencies in populations from the 
African (AFR), East Asian (EAS) and South Asian (SAS) meta-populations to allele frequencies in the 
CEU groups, and allele frequencies in populations from the American (AMR) and European (EUR) 
meta-populations to allele frequencies in the YRI group. For the detection of candidate variants for 
positive selection based on FST values, we used an outlier approach and considered LoF mutations 
presenting FST values located in the top 5% of the distribution of FST genome-wide. We identified 32 
LoF mutations presenting high FST values in at least one population, in 32 genes (including 8 mutations 
located in OR genes). For haplotype-based iHS score calculations, we first defined the derived allele 
state of each SNP based on the 6-EPO alignment, and retained only SNPs with a derived allele 
frequency (DAF) between 10% and 90% to maximize the power of iHS to detect selective signals. 
These additional filters led to a total of 68 LoF mutations to be investigated. We calculated iHS scores 
in 100 kb windows with custom-generated scripts and normalized values. For the detection of selection 
events targeting derived alleles, we considered LoF mutations located in the top 5% most negative iHS 
values genome-wide and found a total of 15 LoF mutations with iHS scores in the lowest 5% of t iHS 
values genome-wide in at least one population (including 1 mutation located in an OR gene).  
 
Data and Materials Availability 
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Legends for figures 
Figure 1. Functional consequences of LoF variants defining the set of dispensable protein-
coding genes.  
Barplots show the distribution of LoF variants defining the set of dispensable genes according to their 
molecular consequences (stop-gains, frameshifts and splice-disrupting variants, SDVs) and the 
predicted severity of their functional impact: low probability (light gray) and high probably LoF (dark 
red; Methods). 
Figure 2. Distribution of the set of dispensable genes in organ-expressed genes and adaptive 
and innate leukocytes-expressed genes, defined from gene expression datasets.  
Relative enrichment in dispensable genes among different gene sets defined from expression datasets 
based on RNA-seq expression data from the Illumina Body Map project (IBM), the GTEX project and 
the BluePrint project (adaptive and innate leukocytes). Organ-expressed genes are further classified 
into two subcategories: organ-specific and organ-pervasive genes (see text). The ratio of dispensable 
genes versus the total size of each category is indicated. Results are presented separately for 17948 
non-OR genes (A) and 355 OR genes (B) for which expression data could be retrieved, from an initial 
list of 20232 protein-coding genes (Methods). P-values for two-tailed Fisher’s exact tests comparing 
the fraction of dispensable genes among the gene subsets against the reference background are 
reported in the text. 
Figure 3. Distribution of dispensable genes across the five human populations considered 
The numbers of dispensable non-OR genes (A) and dispensable OR genes (B) in each population 
(>1% homozygous LoF frequency in a given population) are represented across five categories, 
indicating whether the gene is dispensable in all five populations considered, four, three or two of them, 
or is a population-specific dispensable gene. The five populations considered were: Africans (including 
African American, AFR), Americans (AMR), East Asians (EAS), Europeans (Finnish and Non-Finnish; 
EUR) and South Asians (SAS). The homozygous LoF variant frequencies were taken from the 
GnomAD dataset for the purposes of this analysis.  
Figure 4. Distribution of functional scores relating to gene essentiality/redundancy in the 
stringent set of dispensable genes.  
Score distributions presented include: A. Gene damage index (GDI). B. Residual variation intolerance 
scores (RVIS). C. Probability of being intolerant to both heterozygous and homozygous LoF variants 
(pLI). D. Probability of being intolerant to homozygous LoF variants (pRec). E. Proportion of non-lethal 
non-synonymous mutations, f, estimated by SnIPRE. F. Inter-species conservation, estimated by 
GerpRS (Methods). Panels display the distribution of scores across dispensable non-OR genes (light 
green), non-dispensable non-OR genes (dark green), dispensable OR genes (light purple) and non-
dispensable OR genes (dark purple). Two-tailed Wilcoxon test p-values comparing the distribution of 
dispensable non-OR genes to that of non-dispensable non-OR genes: (A) p-value=6.52e-35; (B) p-
value=1.30e-37;(C) p-value=1.55e-22; (D) p-value=2.94e-01; (E) p-value=1.51e-29; (F) p-
value=9.70e-28. Two-tailed Wilcoxon test p-values comparing the distribution of dispensable OR genes 
28 
 
to that of non-dispensable OR genes: (A) p-value=3.04e-06; (B) p-value=1.96e-02; (C) p-value=4.64e-
01; (D) p-value=7.98e-01; (E) p-value=6.81e-02; (F) p-value=1.85e-02.  
Figure 5. Evidence for positive selection on common LoF alleles. A. Empirical p-values for 32 LoF 
mutations presenting FST scores measuring allele frequency differentiation, in the 95th percentile of 
highest values genome-wide, in at least one population. B. Empirical p-values for 15 LoF mutations 
presenting integrated haplotype scores (iHS) below the 5th percentile of the lowest values genome-
wide (i.e. selection on the LoF allele), in at least one population. FST and iHS values are reported for 
each of the 26 populations of the 1000 Genomes Project, grouped into five super populations: AFR 
(brown), AMR (orange), EAS (purple), EUR (blue) and SAS (pink). Eight common LoF variants with 
both high FST and low iHS are highlighted. The color gradients indicate the significance of the p-values 
and only polymorphic sites involving common biallelic LoF SNPs from the stringent set predicted to 
have severe damaging functional consequences were considered. 
 
 
